NCT07500922 Menopause Effects on Cortico-reticular Functioning
| NCT ID | NCT07500922 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Jyvaskyla |
| Condition | Menopause |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-04-25 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-04-25 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Post-menopausal women who request to begin hormone-replacement therapy (HRT) are directed to the research team. The participants are tested before beginning HRT, after two months of HRT, and five months of HRT. Tests include strength performance, central nervous system functioning, body composition, resting metabolic rate, and vascular screening. The participants are provided a 12-week training intervention (2 x strength, 2 x endurance per week) that can be voluntarily followed between tests at month 2 and 5. Compliance with the training program is recorded. A minimum of 15 participants are needed a priori, but the investigators aim to recruit and test 20 women.
Eligibility Criteria
Inclusion Criteria: * at least 6 months since their last period but no more than being 5 years post-menopausal * basal follicular-stimulating hormone concentration \> 30 IU/L (confirmed post-recruitment) * willing to start combined hormonal treatment * womb and ovaries intact with normal functioning throughout reproductive age * willing to provide informed consent * does not have any of the exclusion criteria for TMS measurements according to Rossi et al. (2021 Clin Neurophysiol. 132(1):269-306.) (i.e. arterial hypertension, heart attack/seizure history, migraine, pacemaker or cochlear implant or other implanted metal/electronic device) Exclusion Criteria: * classified as excessively obese via BMI assessment (i.e., \>35 kg/m2) * intra-uterine device usage during transition to menopause * cardiovascular or skeletomuscular disease preventing strenuous physical activity * smoker * diagnosed psychiatric illness * epilepsy * other diagnosed injuries/illness affecting the neuromuscular system
Contact & Investigator
Simon Walker, PhD
PRINCIPAL INVESTIGATOR
Universirty of Jyväskylä, Finland
Frequently Asked Questions
Who can join the NCT07500922 clinical trial?
This trial is open to female participants only, aged 50 Years or older, up to 59 Years, studying Menopause. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07500922 currently recruiting?
Yes, NCT07500922 is actively recruiting participants. Contact the research team at simon.walker@jyu.fi for enrollment information.
Where is the NCT07500922 trial being conducted?
This trial is being conducted at Jyväskylä, Finland.
Who is sponsoring the NCT07500922 clinical trial?
NCT07500922 is sponsored by University of Jyvaskyla. The principal investigator is Simon Walker, PhD at Universirty of Jyväskylä, Finland. The trial plans to enroll 20 participants.